The Clorox
The Clorox Company
Key figures
Period Jul 2024 to Jun 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$7.1B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
5.8%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-0.8%
Capital efficiency
★★★★★position among all companies
252.3%
Revenue and profit
Performance, financial position and capital allocation
The Clorox
Recent performance trends
The Clorox
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$7.3 billion | US$7.1 billion | US$7.4 billion | US$7.1 billion | US$7.1 billion |
| Net income | US$0.7 billion | US$0.5 billion | US$0.1 billion | US$0.3 billion | US$0.8 billion |
| Total assets | US$6.3 billion | US$6.2 billion | US$5.9 billion | US$5.8 billion | US$5.6 billion |
| Shareholders' equity | US$0.4 billion | US$0.6 billion | US$0.2 billion | US$0.3 billion | US$0.3 billion |
| Net cash provided by (used in) operating activities | US$1.3 billion | US$0.8 billion | US$1.2 billion | US$0.7 billion | US$1.0 billion |
| Net cash provided by (used in) investing activities | US$-0.5 billion | US$-0.2 billion | US$-0.2 billion | US$-0.2 billion | US$-94.00 million |
| Net cash provided by (used in) financing activities | US$-1.4 billion | US$-0.7 billion | US$-0.8 billion | US$-0.7 billion | US$-0.9 billion |
| Cash and cash equivalents | US$0.3 billion | US$0.2 billion | US$0.4 billion | US$0.2 billion | US$0.2 billion |
Revenue scale in the same industry
The Clorox
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 25 companies
- 29 Eastman ChemicalFY Dec 2025 US$8.8B
- 30 RPM InternationalFY May 2026 US$7.9B
- 31 The CloroxThis companyFY Jun 2025 US$7.1B
- 32 CF Industries HoldingsFY Dec 2025 US$7.1B
- 33 Dupont DE NemoursFY Dec 2025 US$6.8B
- … 23 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.2 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-94.00 million | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.0 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.2 billion | Consolidated | Disclosed |
| Dividends paid | US$0.6 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$0.5 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0.2 billion | Consolidated | Disclosed |
| Net assets | US$0.3 billion | Consolidated | Disclosed |
| Net sales | US$7.1 billion | Consolidated | Disclosed |
| Net income | US$0.8 billion | Consolidated | Disclosed |
| Total assets | US$5.6 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.3 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 5.8% | Consolidated | Calculated |
| Net margin | 11.4% | Consolidated | Calculated |
| Return on equity | 252.3% | Consolidated | Calculated |